Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8025142 | 1.00 | ADRB3 (0.44) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL14175706 | 1.00 | ADRB3 (0.44) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL12669959 | 1.00 | ADRB3 (0.44) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL16120503 | 0.95 | ADRB3 (0.44) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL10210755 | 0.95 | ADRB3 (0.44) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL12762654 | 0.94 | ADRB3 (0.50) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL7918555 | 0.93 | ADRB3 (0.50) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL13783719 | 0.93 | ADRB3 (0.50) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL7920981 | 0.93 | ADRB3 (0.50) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL14175708 | 0.93 | ADRB3 (0.50) | ADRB3ADRA2BADRA2CCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809264-B2 | Quinoxalinyl macrocyclic hepatitis C virus serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809264-B2 | Quinoxalinyl macrocyclic hepatitis C virus serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-7605126-B2 | Acylaminoheteroaryl hepatitis C virus protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-7605126-B2 | Acylaminoheteroaryl hepatitis C virus protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-7566719-B2 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-20090005387-A1 | QUINOXALINYL MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-01-01 | — | — | US | disclosed |
| US-20090005387-A1 | QUINOXALINYL MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-01-01 | — | — | US | disclosed |
| US-20080267917-A1 | N-FUNCTIONALIZED AMIDES AS HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080267917-A1 | N-FUNCTIONALIZED AMIDES AS HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-7368452-B2 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368452-B2 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-20080039470-A1 | Acylaminoheteroaryl hepatitis C virus protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20080039470-A1 | Acylaminoheteroaryl hepatitis C virus protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20080008681-A1 | MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-01-10 | — | — | US | disclosed |
| US-20080008681-A1 | MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-01-10 | — | — | US | disclosed |
| WO-2008002924-A2 | QUINOXALINYL MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-01-03 | — | — | WO | disclosed |
| US-20070299078-A1 | Quinoxalinyl Macrocyclic Hepatitis C Virus Serine Protease Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070060510-A1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2007-03-15 | — | — | US | disclosed |
| US-20070060510-A1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080267917-A1 | N-FUNCTIONALIZED AMIDES AS HEPATITIS C SERINE PROTEASE INHIBITORS | PRSS1, HPN, SPINT2 | ADRB3 4431/4885ADRA2B 4247/4885ADRA2C 3657/4885 |
| US-20080039470-A1 | Acylaminoheteroaryl hepatitis C virus protease inhibitors | ATG4A, CYP4A22, AADAC | ADRB3 3972/4885ADRA2B 4188/4885ADRA2C 3458/4885 |
| US-20080008681-A1 | MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | PRSS1, SPINT2, TMPRSS4 | ADRB3 4428/4885ADRA2B 4667/4885ADRA2C 4106/4885 |
| US-20090005387-A1 | QUINOXALINYL MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | PRSS1, SPINT2, CTSC | ADRB3 4685/4885ADRA2B 4777/4885ADRA2C 4633/4885 |
| US-20070299078-A1 | Quinoxalinyl Macrocyclic Hepatitis C Virus Serine Protease Inhibitors | PRSS1, SPINT2, CTSC | ADRB3 4685/4885ADRA2B 4777/4885ADRA2C 4633/4885 |
| US-20070060510-A1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | PRSS1, SPINT2, HPN | ADRB3 4665/4885ADRA2B 4704/4885ADRA2C 4385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.